What is AJOVY and how does it help children with migraines?

AJOVY is a medication approved by the FDA for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kg or more. It is the first and only CGRP antagonist approved for pediatric migraine prevention, providing a new monthly treatment option that can help reduce the frequency of migraine attacks.

How does the FDA approval of AJOVY for pediatric migraine impact families?

The approval of AJOVY for children and adolescents addresses a long-standing gap in care, as migraines can severely disrupt the daily lives of younger patients. AJOVY offers families a targeted preventive treatment option that can be administered either in-office or at home, providing added convenience and support as they manage this neurological condition.

Home / Health / FDA Approves Pediatric Migraine Treatment with AJOVY

FDA Approves Pediatric Migraine Treatment with AJOVY

Q: What is the significance of Teva's AJOVY expanding to the pediatric market?

Teva's AJOVY becoming the first and only CGRP antagonist approved for pediatric migraine prevention marks an important milestone. It strengthens Teva's commitment to expanding access to neuroscience therapies across age groups, providing a new treatment option for a patient population that has historically had limited preventive options.

6 Aug

•

Summary

FDA approves AJOVY for episodic migraine prevention in children 6-17
AJOVY is the first CGRP antagonist approved for pediatric migraine
Offers monthly treatment option for in-office or at-home use

FDA Approves Pediatric Migraine Treatment with AJOVY

In a significant development, the U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceuticals' AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. This approval marks an important milestone, as AJOVY becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults.

The approval of AJOVY for this younger patient population addresses a long-standing gap in care, as migraines are a common yet often overlooked condition that can severely disrupt the daily lives of children and adolescents. With AJOVY, these patients now have access to a targeted preventive treatment option that can help reduce the frequency of migraine attacks. The monthly injection can be administered either in-office or at home, offering families added convenience and support as they manage this neurological condition.

Teva's Executive Vice President, Chris Fox, emphasized the significance of this development, stating that AJOVY now provides "a new treatment option, addressing a long-standing gap in care and offering families added support as they navigate the challenges of this condition." The approval builds on AJOVY's established success in adult patients since its initial U.S. approval in 2018, further strengthening Teva's commitment to expanding access to neuroscience therapies across age groups.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.